Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
151-165 of 2352 results
IXICO wins four new contracts from pharmaceutical companies and biotechnology firm
IXICO has secured four new contracts from several pharmaceutical companies and a specialist biotechnology company, with a combined value of more than £3m.
Contract Research & Services > Contract Services > News
AMRI signs collaboration deal with New York Center for Nanomedicine Research
Albany Molecular Research (AMRI) has signed a collaboration agreement with the New York Center for Nanomedicine Research (NYCNMR) to co-market their nanotechnology services to global pharmaceutical and biotechnology clients.
Contract Research & Services > Contract Services > News
TheraKine, Cell Care Therapeutics sign license and development deal
TheraKine and Cell Care Therapeutics have entered into a licensing agreement to use TheraKine's injectable sustained release technology to enable Cell Care's stem cell therapies for diseases of the eye that commonly cause blindness.
Contract Research & Services > Contract Services > News
Cepheid forms diagnostic collaboration with MedImmune and COMBACTE
Cepheid has formed a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients.
Contract Research & Services > Contract Services > News
Debiopharm, EORTC partner to investigate Triptorelin for treatment of salivary gland cancers
Debiopharm International has announced a collaboration in order to supply triptorelin pamoate 3.75 mg 1-month formulation for patients suffering from salivary cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).
Contract Research & Services > Contract Services > News
Cytori Therapeutics signs deal with Idis to launch managed access program in EMEA
Cytori Therapeutics has entered into an agreement with Idis Managed Access, part of the Clinigen Group, to establish a Managed Access Program (MAP) in select countries across Europe, the Middle East, and Africa for patients with impaired hand function due to scleroderma.
Contract Research & Services > Contract Services > News
Novartis expands immuno-oncology pipeline through collaboration with Surface Oncology
Novartis has expanded its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology.
Contract Research & Services > Contract Services > News
Sorrento, Karolinska Institutet partner to perform immuno-oncology research
Sorrento Therapeutics has formed a partnership with the Karolinska Institutet (KI) in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.
Contract Research & Services > Contract Services > News
AAA inks deal with Johns Hopkins University to develop PSMA receptor ligand in prostate cancer
Advanced Accelerator Applications (AAA) has signed an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes.
Contract Research & Services > Contract Services > News
Akashi Therapeutics partners with Grünenthal Group on HT-100 for Duchenne muscular dystrophy
Akashi Therapeutics has formed a $100m partnership with Grünenthal Group for a global drug development program for the investigational therapeutic HT-100, an orally available small molecule drug candidate in Phase 1b/2a for the reduction of fibrosis and inflammation, and promotion of healthy muscle fiber regeneration in Duchenne muscular dystrophy (DMD).
Contract Research & Services > Contract Services > News
Apogenix receives first milestone payment from CANbridge licensing agreement
Apogenix has reached the first milestone of its licensing agreement with CANbridge Life Sciences for the development and commercialization of lead immuno-oncology candidate APG101 in China, Macao, and Hong Kong.
Contract Research & Services > Contract Services > News
Teva, Checkpoint Therapeutics sign license agreement for Oral PARP inhibitor
Teva Pharmaceutical Industries and Checkpoint Therapeutics have signed a license agreement in which Checkpoint will obtain the exclusive worldwide rights to develop and commercialize CEP-8983 and its small molecule prodrug, CEP-9722, an oral poly (ADP-ribose) polymerase (PARP) inhibitor in early clinical development for solid tumors.
Contract Research & Services > Contract Services > News
Vernalis selects Corvus Pharmaceuticals as global licensee for adenosine antagonist program
Vernalis has selected Corvus Pharmaceuticals as its licensee for their adenosine antagonist program.
Contract Research & Services > Contract Services > News
Sanofi ends deal with MannKind for Afrezza inhaled insulin
By PBR Staff Writer
Sanofi has ended its collaboration with MannKind for the development and commercialization of Afrezza (insulin human) inhalation powder.
Contract Research & Services > Contract Services > News
VIVUS unveils intent to reacquire US and Canadian rights for Stendra
VIVUS has been notified by Auxilium Pharmaceuticals, a subsidiary of Endo International, of Auxilium's intention to return the US and Canadian commercial rights for STENDRA (Avanafil) to VIVUS.
Contract Research & Services > Contract Services > News
151-165 of 2352 results